DekaBank Deutsche Girozentrale Acquires 17,085 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

DekaBank Deutsche Girozentrale grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,057,579 shares of the biopharmaceutical company's stock after purchasing an additional 17,085 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.17% of Gilead Sciences worth $229,294,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Redwood Financial Network Corp lifted its position in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC raised its holdings in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after buying an additional 99 shares during the last quarter. Nicolet Advisory Services LLC boosted its position in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares during the period. Peak Financial Advisors LLC boosted its position in shares of Gilead Sciences by 1.7% during the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after buying an additional 100 shares during the period. Finally, Perkins Coie Trust Co increased its position in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.0%

Shares of NASDAQ:GILD traded up $2.18 during mid-day trading on Wednesday, hitting $113.24. The stock had a trading volume of 5,234,322 shares, compared to its average volume of 7,698,493. Gilead Sciences, Inc. has a 12-month low of $67.65 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a market cap of $140.86 billion, a PE ratio of 23.84, a P/E/G ratio of 0.72 and a beta of 0.29. The company's 50 day moving average is $107.26 and its 200-day moving average is $104.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the firm posted ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.79%. Gilead Sciences's dividend payout ratio is 66.53%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer owned 165,110 shares in the company, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the sale, the insider directly owned 120,168 shares of the company's stock, valued at $13,238,908.56. This trade represents a 2.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock valued at $6,340,745 over the last three months. 0.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.